Displaying 1–10 of 19 news results
May 18, 2021 The Foundation in the News
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
Feb 4, 2021 The Foundation in the News
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
Jan 29, 2021 The Foundation in the News
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Dec 16, 2020 The Foundation in the News
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
Dec 14, 2020 The Foundation in the News
Live stream ceremony will include Art Garfunkel, Diane Schuur, and Margaret Atwood. A tribute will also be made to Justice Ruth Bader Ginsburg.
Nov 9, 2020 The Foundation in the News
The Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
Oct 29, 2020 The Foundation in the News
Oct 28, 2020 The Foundation in the News
Oct 7, 2020 The Foundation in the News
Aug 5, 2020 The Foundation in the News
In 2018, the Foundation Fighting Blindness launched a venture philanthropy investment arm called the Retinal Degeneration (RD) Fund to help companies and researchers advance promising treatments for inherited retinal diseases into and through early-stage human studies. Currently, the RD Fund has allocated about 75% of its $72 million fund to eight investments.